

Alberto Zamora

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/912702/publications.pdf>

Version: 2024-02-01

34
papers

852
citations

566801

15
h-index

500791

28
g-index

40
all docs

40
docs citations

40
times ranked

1411
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 157-164.	1.4	64
2	<scp>HTE</scp> 3.0: Knowledge-based systems in cascade for familial hypercholesterolemia detection and dyslipidemia treatment. <i>Expert Systems</i> , 2022, 39, e12835.	2.9	2
3	Long-term exposure to PM10 above WHO guidelines exacerbates COVID-19 severity and mortality. <i>Environment International</i> , 2022, 158, 106930.	4.8	32
4	Codesign and Feasibility Testing of a Tool to Evaluate Overweight and Obesity Apps. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5387.	1.2	0
5	El rastreo masivo de datos es una segunda oportunidad para mejorar el manejo de los pacientes fenotipo de hipercolesterolemia familiar. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2021, 33, 138-147.	0.4	1
6	Low HDL and high triglycerides predict COVID-19 severity. <i>Scientific Reports</i> , 2021, 11, 7217.	1.6	122
7	Massive data screening is a second opportunity to improve the management of patients with familial hypercholesterolemia phenotype. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2021, 33, 138-147.	0.1	2
8	Three-year events and mortality in cardiovascular disease patients without lipid-lowering treatment. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 2102-2104.	0.8	1
9	Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype. <i>Atherosclerosis</i> , 2020, 292, 42-51.	0.4	9
10	Polygenic Markers in Patients Diagnosed of Autosomal Dominant Hypercholesterolemia in Catalonia: Distribution of Weighted LDL-c-Raising SNP Scores and Refinement of Variant Selection. <i>Biomedicines</i> , 2020, 8, 353.	1.4	6
11	Heart failure, zip code, and telemetry: a trinomial in need of understanding. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 168-170.	0.1	0
12	Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction. <i>Open Heart</i> , 2020, 7, e001169.	0.9	3
13	Evaluation Criteria for Weight Management Apps: Validation Using a Modified Delphi Process. <i>JMIR MHealth and UHealth</i> , 2020, 8, e16899.	1.8	8
14	Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 1080.	1.0	33
15	Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 519-520.	0.4	1
16	Estimaci3n del porcentaje de pacientes con enfermedad coronaria estable candidatos a recibir inhibidores de PCSK9. <i>Respuesta. Revista Espanola De Cardiologia</i> , 2019, 72, 519-520.	0.6	3
17	Assessment of the Efficacy, Safety, and Effectiveness of Weight Control and Obesity Management Mobile Health Interventions: Systematic Review. <i>JMIR MHealth and UHealth</i> , 2019, 7, e12612.	1.8	29
18	Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 1010-1017.	0.4	10

#	ARTICLE	IF	CITATIONS
19	Número de pacientes candidatos a recibir inhibidores de la PCSK9 según datos de 2,5 millones de participantes de la práctica clínica real. Revista Espanola De Cardiologia, 2018, 71, 1010-1017.	0.6	23
20	Acute Myocardial Infarction Population Incidence and Mortality Rates, and 28-day Case-fatality in Older Adults. The REGICOR Study. Revista Espanola De Cardiologia (English Ed), 2018, 71, 718-725.	0.4	11
21	Analysis of Plasma Albumin, Vitamin D, and Apolipoproteins A and B as Predictive Coronary Risk Biomarkers in the REGICOR Study. Revista Espanola De Cardiologia (English Ed), 2018, 71, 910-916.	0.4	6
22	Tasas de incidencia y mortalidad, y letalidad poblacional a 28 días del infarto agudo de miocardio en adultos mayores. Estudio REGICOR. Revista Espanola De Cardiologia, 2018, 71, 718-725.	0.6	10
23	Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients. Journal of Clinical Lipidology, 2017, 11, 1013-1022.	0.6	61
24	The association between education and cardiovascular disease incidence is mediated by hypertension, diabetes, and body mass index. Scientific Reports, 2017, 7, 12370.	1.6	70
25	Evaluation of a Clinical Decision Support System for Dyslipidemia Treatment (HTE-DLPR) by QoE questionnaire. International Journal of Cardiovascular Practice, 2017, 2, 10-16.	0.2	0
26	Impacto teórico en la enfermedad coronaria de usar un sistema informatizado de ayuda en la prescripción del tratamiento hipolipemiante. Revista Espanola De Cardiologia, 2015, 68, 75-78.	0.6	1
27	Theoretical Impact on Coronary Disease of Using a Computerized Clinical Decision Support System in the Prescription of Lipid-lowering Treatment. Revista Espanola De Cardiologia (English Ed), 2015, 68, 75-78.	0.4	2
28	Pilot study to validate a computer-based clinical decision support system for dyslipidemia treatment (HTE-DLP). Atherosclerosis, 2013, 231, 401-404.	0.4	38
29	Impact of a Partial Smoke-Free Legislation on Myocardial Infarction Incidence, Mortality and Case-Fatality in a Population-Based Registry: The REGICOR Study. PLoS ONE, 2013, 8, e53722.	1.1	61
30	Blood pressure variation activity/rest in the last 4h of 24-hour ambulatory blood pressure monitoring is associated to a poor cardiovascular prognosis in patients with acute coronary syndrome. International Journal of Cardiology, 2009, 137, S14-S15.	0.8	0
31	Relationship of classical and non-classical risk factors with genetic variants relevant to coronary heart disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 738-744.	3.1	24
32	A polymorphism in the promoter of the tumor necrosis factor- α gene (α 308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis, 2003, 167, 257-264.	0.4	104
33	Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clinical Biochemistry, 2002, 35, 197-203.	0.8	46
34	Recovery of Minimal Change Nephrotic Syndrome and Acute Renal Failure in a Patient with Renal Cell Carcinoma. American Journal of Nephrology, 1998, 18, 433-435.	1.4	21